Further analyses suggested that variation in MGMT assay results between pyrosequencing and methylation array for IDHwt GBM may be driven by differing MGMT pyrosequencing cutoff values and divergent results in low-VAF GBMs specifically. This evidence concerns the gene MGMT and glioblastoma.